Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States

…, PL Juneau, L Spangler, FM Mirza, BS Stolshek - Journal of managed …, 2015 - jmcp.org
… Cheng, Spangler, and Stolshek are employees, and Mirza was an employee, of Amgen.
Study concept and design were contributed by Cheng, Stolshek, and Durden, with assistance …

Assessing health-related quality-of-life and health state preference in persons with obesity: a validation study

…, MG Cisternas, DJ Pasta, BS Stolshek… - Quality of Life …, 1997 - Springer
The objective of this study was to assess the reliability, validity and responsiveness of a new
health-related quality-of-life (HRQOL) measure containing global and obesity-specific …

Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma

E Chrischilles, DJ Delgado, BS Stolshek… - Cancer …, 2002 - journals.sagepub.com
Background In intermediate-grade non-Hodgkin's lymphoma (NHL) patients, full-dose
CHOP improves survival but increases myelosuppression, causing febrile neutropenia …

[PDF][PDF] Days of prophylactic filgrastim use to reduce febrile neutropenia in patients

SJ Scott, BS Stolshek, M Fridman, DJ Delgado… - Journal of managed …, 2003 - jmcp.org
… Delgado and Bradley S. Stolshek are employees and shareholders of Amgen, and Scott …
Drafting of the manuscript was the work of Delgado, Scott, Stolshek, and Fridman; critical …

[HTML][HTML] Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry

LR Harrold, BS Stolshek, S Rebello, DH Collier… - Clinical …, 2017 - Springer
Psoriatic arthritis (PsA) is a chronic condition characterized by a diverse set of symptoms, from
swollen joints to nail disease to skin disease. A variety of treatment options are available, …

Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan

SW Wade, JR Curtis, J Yu, J White, BS Stolshek… - Bone, 2012 - Elsevier
The association between bisphosphonate adherence in the first 12months after therapy
initiation and subsequent fracture risk was examined. Patients were identified from a large, …

Osteoporosis medication adherence: physician perceptions vs. patients' utilization

JR Curtis, Q Cai, SW Wade, BS Stolshek, JL Adams… - Bone, 2013 - Elsevier
Few data are available on physician perceptions of osteoporosis medication adherence.
This study compared physician-estimated medication adherence with adherence calculated …

[HTML][HTML] A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in …

…, J White, D Van Voorhis, D Tang, BS Stolshek - Advances in …, 2016 - Springer
Introduction Biologic therapies are used to treat several inflammatory diseases, including
rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (…

Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy

…, JR Curtis, J Yu, J White, BS Stolshek… - … health economics and …, 2012 - Springer
Background Osteoporosis is a common condition and the economic burden of osteoporosis-related
fractures is significant. While studies have reported the incremental or attributable …

[HTML][HTML] Impact of osteoporosis on high-cost chronic diseases

SW Thayer, BS Stolshek, GG Rey, JG Seare - Value in Health, 2014 - Elsevier
Objective To assess the impact of osteoporosis on health care costs for patients with chronic
disease (CD): cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD…